Immunotech Biopharm Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	41.04	44.54	53.22	97.71	104.25
Research & Development	132.82	154.24	177.33	176.22	240.61
Other Operating Expenses	1.21	2.12	0.5	0.29	0.29
Operating Expenses	175.07	200.9	231.05	274.22	345.15
Operating Income	-175.07	-200.9	-231.05	-274.22	-345.15
Interest Expense	-6.81	-7.49	-8.52	-6.14	-3.68
Interest & Investment Income	0.53	1.07	3.01	3.2	7.56
Currency Exchange Gain (Loss)	-0.6	0.22	-0.07	0.09	-6.27
Other Non Operating Income (Expenses)	-49.13	60.39	-9.23	-5.62	10.51
EBT Excluding Unusual Items	-231.07	-146.71	-245.85	-282.69	-337.03
Gain (Loss) on Sale of Investments	0.19	-19.81	-90.01	-24.02	-18.79
Gain (Loss) on Sale of Assets	-0.03	-0.04	0.2	-0.64	-0.09
Asset Writedown	-	-19.88	-	-	1.3
Other Unusual Items	-	0.02	0.19	-13.75	-
Pretax Income	-230.91	-186.42	-335.48	-321.1	-354.62
Income Tax Expense	-	0.93	-	-	-
Earnings From Continuing Operations	-230.91	-187.34	-335.48	-321.1	-354.62
Minority Interest in Earnings	0.12	0.43	0.66	2.99	0.39
Net Income	-230.79	-186.91	-334.82	-318.11	-354.22
Net Income to Common	-230.79	-186.91	-334.82	-318.11	-354.22
Shares Outstanding (Basic)	549	515	515	515	515
Shares Outstanding (Diluted)	549	515	515	515	515
Shares Change (YoY)	6.69%	-	-	-	15.95%
EPS (Basic)	-0.42	-0.36	-0.65	-0.62	-0.69
EPS (Diluted)	-0.42	-0.36	-0.65	-0.62	-0.69
Free Cash Flow	-	-153	-183.21	-249.07	-400.67
Free Cash Flow Per Share	-	-0.30	-0.36	-0.48	-0.78
EBITDA	-115.77	-141.6	-178.83	-231.11	-324.33
D&A For EBITDA	59.3	59.3	52.22	43.11	20.82
EBIT	-175.07	-200.9	-231.05	-274.22	-345.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.